BioSpace News Archive

Sunstone Therapies, a leader in the development of clinical trials and the delivery of psychedelic-assisted therapy in the medical setting, today announces the publication of positive phase 2 data, assessing the effect of psilocybin therapy for patients with cancer and major depression disorder (MDD), in JAMA Oncology.

Pressure BioSciences, Inc. (OTCQB:PBIO) (“PBI” and the “Company”) today announced that the Company will host a teleconference to discuss its Fiscal Year 2022 financial results and to provide a business update.

Caris Life Sciences®(Caris) and Flare Therapeutics today announced a multi-year strategic collaboration to accelerate precision medicine approaches across five of Flare’s therapeutic programs into clinical trials through advanced molecular profiling approaches that guide patient selection and participation.

Imperial College London’s Professor of Hepatology, Mark Thursz, has been appointed to the Scientific Advisory Board of HepaTx (the SAB), a biotechnology company focused on cell therapy liver diseases

Nurix Therapeutics, Inc. (Nasdaq: NRIX) today reported financial results for the first quarter ended February 28, 2023 and provided a corporate update.

Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will be the featured speaker in a fireside chat at the 22nd Annual Needham Healthcare Conference.

PepGen Inc. (Nasdaq: PEPG) today announced that James McArthur, Ph.D., President and CEO of PepGen will present at the 22nd Annual Needham Virtual Healthcare Conference on Thursday, April 20th at 8:00am EDT.